ADVANCE-ID is pleased to share a significant milestone in the Phase 2b RIV-CARE clinical trial, following BioVersys’ announcement on 29 October 2026 of the first patient first visit in the study.
RIV-CARE is an open-label Phase 2b clinical trial evaluating BV100, an investigational antibiotic, in combination with low-dose polymyxin B and other antibiotics for the treatment of serious infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The trial aims to enrol approximately 100 patients and assess the safety and efficacy of BV100-based combination therapies compared with best available treatment in settings with high levels of antimicrobial resistance.
Conducted by the ADVANCE-ID clinical trial network with funding support from Wellcome, the study represents an important collaborative effort to address the urgent need for effective treatment options against multidrug-resistant bacterial infections.
This milestone marks an important step forward in ADVANCE-ID’s mission to generate robust clinical evidence and accelerate research into innovative treatments for antimicrobial-resistant infections.
The trial’s interim analysis is expected in the first half of 2027.
References / links
BioVersys official announcement: https://ir.bioversys.com/news/bioversys-announces-first-patient-first-visit-in-phase-2b-riv-care-trial-of-bv100/578dc298-5e66-4843-b63c-4f6fb0c3d4ae
